Richard G. Langley

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

Richard G. Langley, Boni E. Elewski, Mark Lebwohl et al. · New England Journal of Medicine · 2014 · 1.9K citations · Full text

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Kim Papp, Richard G. Langley, Mark Lebwohl et al. · The Lancet · 2008 · 1.3K citations

Immunology, Clinical Trials, Clinical Dermatology +7

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Alan Menter, Stephen K. Tyring, Kenneth B. Gordon et al. · Journal of the American Academy of Dermatology · 2007 · 869 citations

Autoimmune Disease, Systemic Treatment, Severe Psoriasis +7

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

Kenneth B. Gordon, Andrew Blauvelt, Kim Papp et al. · New England Journal of Medicine · 2016 · 818 citations · Full text

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

Mark Lebwohl, Bruce Strober, Alan Menter et al. · New England Journal of Medicine · 2015 · 790 citations · Full text